Affiliation:
1. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
2. Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
Abstract
Depression, commonly treated with antidepressants, is associated with an increased risk of dementia, especially in older adults. However, the association between antidepressant use and dementia risk is unclear. We searched for randomized controlled trials and observational studies from PubMed, Embase, and Cochrane on 1 February 2022, restricting to full texts in English. Since dementia is a chronic disease requiring a long induction time, we restricted studies with ≥1 year follow-up. We extracted the relative risk (RR) adjusted for the most variables from each study and evaluated the heterogeneity using I square (I2). The protocol was registered in the PROSPERO International Register of Systematic Reviews (CRD42022338038). We included six articles in the systematic review, of which the sample size ranged from 716 to 141,740, and the median length of follow-up was 5 years. The pooled RR was 1.21 (95% CI = 1.12–1.29) with an I2 of 71%. Our findings suggest that antidepressant use was associated with an increased risk of dementia in older adults with depression, yet moderate to high heterogeneity existed across studies. Future work accounting for the depression progression is needed to differentiate the effect of depression and antidepressants on dementia risk.
Reference47 articles.
1. Emmady, P.D., Schoo, C., and Tadi, P. (2022). StatPearls, StatPearls Publishing.
2. Prevalence of dementia in the United States: The aging, demographics, and memory study;Plassman;Neuroepidemiology,2007
3. Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies;Wang;Behav. Neurol.,2018
4. The economic and societal burden of Alzheimer disease: Managed care considerations;Skaria;Am. J. Manag. Care,2022
5. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019;Nichols;Lancet Public Health,2022